Affiliations 

  • 1 Department of Biomedical Science, Faculty of Medicine, University of Malaya, Kuala Lumpur 50603, Malaysia. nurizyanikamaruzman@gmail.com
  • 2 Centre for Virus and Vaccine Research (CVVR), Sunway University, 47500 Subang Jaya, Selangor, Malaysia. norainiaa@sunway.edu.my
  • 3 Centre for Virus and Vaccine Research (CVVR), Sunway University, 47500 Subang Jaya, Selangor, Malaysia. pohcl@sunway.edu.my
  • 4 Jeffrey Cheah School of Medicine and Health Sciences, Monash University Malaysia, Subang Jaya 47500, Selangor, Malaysia. md.ezharul.hoque@monash.edu
Cancers (Basel), 2019 May 06;11(5).
PMID: 31064156 DOI: 10.3390/cancers11050632

Abstract

Overexpression of oncogenes and cross-talks of the oncoproteins-regulated signaling cascades with other intracellular pathways in breast cancer could lead to massive abnormal signaling with the consequence of tumorigenesis. The ability to identify the genes having vital roles in cancer development would give a promising therapeutics strategy in combating the disease. Genetic manipulations through siRNAs targeting the complementary sequence of the oncogenic mRNA in breast cancer is one of the promising approaches that can be harnessed to develop more efficient treatments for breast cancer. In this review, we highlighted the effects of major signaling pathways stimulated by oncogene products on breast tumorigenesis and discussed the potential therapeutic strategies for targeted delivery of siRNAs with nanoparticles in suppressing the stimulated signaling pathways.

* Title and MeSH Headings from MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.